Following a successful pilot, the Pet Buddies program will give company's scientifically proven hypoallergenic cats free of cost to allergic children undergoing treatment for life-threatening diseases
LAS VEGAS, June 24 /PRNewswire/ -- Those who have a companion animal understand that the human-animal bond provides important benefits, including the positive effects on those undergoing therapy for life-threatening diseases. Following a successful pilot conducted in 2008, ALLERCA Lifestyle Pets officially launches its Pet Buddies program to provide the company's hypoallergenic kittens at no cost to pet-allergic children undergoing long-term medical treatment.
Many of these children dream of pet companionship but are unable to do so because they suffer from allergies that are further exacerbated by some of the treatments they are undergoing. The results of the pilot Pet Buddies program demonstrated the positive benefits to recovery that a pet can bring to these children, with further confirmation coming from parents.
Both ALLERCA Lifestyle Pets and its customers help fund the program. For each client who purchases a hypoallergenic kitten, ALLERCA Lifestyle Pets donates a kitten to the Pet Buddies program.
In 2010, ALLERCA Lifestyle Pets will introduce the company's hypoallergenic dog, the Jabari GD to the Pet Buddies program. With 100% success rate to date, the JABARI GD has proven to be the only genuine option for canine-allergic individuals who wish to own a dog.
Candidates for the Pet Buddies program are children under 18 years of age who are in remission from a life-threatening disease and who are in low-income families or where the families have experienced hardship due to the cost of the child's medical treatment. Each potential Pet Buddies family is required to undergo an application and vetting process, and may be asked to cover some basic costs such as transportation, not to exceed $500.
Contact: Simon Brodie 888-479-1113 firstname.lastname@example.org
|SOURCE ALLERCA Lifestyle Pets|
Copyright©2009 PR Newswire.
All rights reserved